Literature DB >> 23578591

Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

Jing Wen1, Yumin Xia, Ariel Stock, Jennifer S Michaelson, Linda C Burkly, Maria Gulinello, Chaim Putterman.   

Abstract

Given the early onset of neuropsychiatric disease and the potential response to immunosuppressive therapy, neuropsychiatric disease is considered a primary disease manifestation in systemic lupus erythematosus (SLE). However, the pathogenesis is not fully understood and optimal treatment has yet to be determined. TWEAK is a TNF family ligand that mediates pleotropic effects through its receptor Fn14, including the stimulation of inflammatory cytokine production by astrocytes, endothelial cells, and other non-hematopeotic cell types, and induction of neuronal death. Furthermore, TWEAK-inducible mediators are implicated in neuropsychiatric lupus. Thus, we hypothesized that the TWEAK/Fn14 pathway may be involved in the pathogenesis of neuropsychiatric SLE. We generated MRL-lpr/lpr (MRL/lpr) mice deficient for Fn14, the sole known signaling receptor for TWEAK. Neuropsychiatric disease was compared in age- and gender-matched MRL/lpr Fn14 wild type (WT) and knockout (KO) mice, using a comprehensive battery of neurobehavioral tests. We found that MRL/lpr Fn14WT mice displayed profound depression-like behavior as seen by increased immobility in a forced swim test and loss of preference for sweetened fluids, which were significantly ameliorated in Fn14KO mice. Similarly, MRL/lpr Fn14WT mice had impaired cognition, and this was significantly improved in Fn14KO mice. To determine the mechanism by which Fn14 deficiency ameliorates neuropsychiatric disease, we assessed the serum levels of autoantibodies and local expression of cytokines in the cortex and hippocampus of lupus mice. No significant differences were found in the serum levels of antibodies to nuclear antigens, or autoantibodies specifically associated with neuropsychiatric disease, between MRL/lpr Fn14WT and KO mice. However, MRL/lpr Fn14KO mice had significantly decreased brain expression of RANTES, C3, and other proinflammatory mediators. Furthermore, MRL/lpr Fn14KO mice displayed improved blood brain barrier integrity. In conclusion, several central manifestations of neuropsychiatric lupus, including depression-like behavior and altered cognition, are normalized in MRL/lpr mice lacking Fn14. Our results are the first to indicate a role for the TWEAK/Fn14 pathway in the pathogenesis of neuropsychiatric lupus, and suggest this ligand-receptor pair as a potential therapeutic target for a common and dangerous disease manifestation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578591      PMCID: PMC3672366          DOI: 10.1016/j.jaut.2013.03.002

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  52 in total

Review 1.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

Review 2.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome.

Authors:  Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2007-01-26       Impact factor: 5.532

Review 3.  TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease.

Authors:  Linda C Burkly; Jennifer S Michaelson; Kyungmin Hahm; Aniela Jakubowski; Timothy S Zheng
Journal:  Cytokine       Date:  2007-11-05       Impact factor: 3.861

Review 4.  The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.

Authors:  N Müller; M J Schwarz
Journal:  Mol Psychiatry       Date:  2007-04-24       Impact factor: 15.992

5.  Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin.

Authors:  Yasuhiro Katsumata; Masayoshi Harigai; Yasushi Kawaguchi; Chikako Fukasawa; Makoto Soejima; Kae Takagi; Michi Tanaka; Hisae Ichida; Akiko Tochimoto; Tokiko Kanno; Katsuji Nishimura; Naoyuki Kamatani; Masako Hara
Journal:  J Rheumatol       Date:  2007-09-15       Impact factor: 4.666

6.  Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.

Authors:  Sheila M Fleming; Nicole A Tetreault; Caitlin K Mulligan; Ché B Hutson; Eliezer Masliah; Marie-Françoise Chesselet
Journal:  Eur J Neurosci       Date:  2008-07       Impact factor: 3.386

Review 7.  TWEAK and the central nervous system.

Authors:  Manuel Yepes
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

8.  Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.

Authors:  Yumin Xia; Sean R Campbell; Anna Broder; Leal Herlitz; Maria Abadi; Ping Wu; Jennifer S Michaelson; Linda C Burkly; Chaim Putterman
Journal:  Clin Immunol       Date:  2012-08-20       Impact factor: 3.969

9.  Alpha-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice.

Authors:  Bisram Deocharan; Zhijie Zhou; Kochnaf Antar; Linda Siconolfi-Baez; Ruth Hogue Angeletti; John Hardin; Chaim Putterman
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

10.  Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus.

Authors:  Katsuji Nishimura; Masayoshi Harigai; Masako Omori; Eri Sato; Masako Hara
Journal:  Psychoneuroendocrinology       Date:  2008-02-07       Impact factor: 4.905

View more
  48 in total

1.  Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice.

Authors:  Jing Wen; Christopher Holden Chen; Ariel Stock; Jessica Doerner; Maria Gulinello; Chaim Putterman
Journal:  Brain Behav Immun       Date:  2015-12-23       Impact factor: 7.217

Review 2.  Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches.

Authors:  Aida Zarfeshani; Kaitlin R Carroll; Bruce T Volpe; Betty Diamond
Journal:  Curr Rheumatol Rep       Date:  2021-03-29       Impact factor: 4.592

Review 3.  The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface.

Authors:  Ariel D Stock; Sivan Gelb; Ofer Pasternak; Ayal Ben-Zvi; Chaim Putterman
Journal:  Autoimmun Rev       Date:  2017-04-17       Impact factor: 9.754

Review 4.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

Review 5.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

6.  Conjugated linoleic acid prevents age-dependent neurodegeneration in a mouse model of neuropsychiatric lupus via the activation of an adaptive response.

Authors:  Antonio Monaco; Ida Ferrandino; Floriana Boscaino; Ennio Cocca; Luisa Cigliano; Francesco Maurano; Diomira Luongo; Maria Stefania Spagnuolo; Mauro Rossi; Paolo Bergamo
Journal:  J Lipid Res       Date:  2017-11-22       Impact factor: 5.922

Review 7.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

8.  TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.

Authors:  Jing Wen; Jessica Doerner; Karen Weidenheim; Yumin Xia; Ariel Stock; Jennifer S Michaelson; Kuti Baruch; Aleksandra Deczkowska; Maria Gulinello; Michal Schwartz; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2015-04-22       Impact factor: 7.094

9.  CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.

Authors:  Samantha A Chalmers; Jing Wen; Justine Shum; Jessica Doerner; Leal Herlitz; Chaim Putterman
Journal:  Clin Immunol       Date:  2016-08-26       Impact factor: 3.969

Review 10.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.